These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27093896)

  • 21. Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1.
    Rigato I; Cravatari M; Avellini C; Ponte E; Crocè SL; Tiribelli C
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):403-8. PubMed ID: 17607296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John's wort). Case of drug interaction?
    Etogo-Asse F; Boemer F; Sempoux C; Geubel A
    Acta Gastroenterol Belg; 2008; 71(1):36-8. PubMed ID: 18396749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial.
    Morais-Socorro M; Cavalcanti MA; Martins R; Neto Francisco P; Rezende A; Azevedo G; Almeida M
    Gynecol Endocrinol; 2012 Jun; 28(6):483-7. PubMed ID: 22132809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator.
    Campisi R; Marengo FD
    Cardiovasc Drug Rev; 2007; 25(2):132-45. PubMed ID: 17614936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
    Kenemans P
    Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
    [No Abstract]   [Full Text] [Related]  

  • 27. Tibolone (Livial) enhances warfarin-induced anticoagulation in postmenopausal women.
    Elbers J; Hageluken C; Wadham A
    Maturitas; 2007 Jan; 56(1):94-100. PubMed ID: 16887301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tibolone in the treatment of menopause: compliance, efficacy and safety in a ten year experience.
    Bianco V; Murina F; Roberti P; Valente I
    Minerva Ginecol; 2006 Aug; 58(4):335-44. PubMed ID: 16957677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis in the endometrium of postmenopausal women receiving tibolone.
    Gökaslan H; Oktem O; Durmuşoglu F; Eren F
    Gynecol Obstet Invest; 2003; 56(3):124-7. PubMed ID: 14504425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial cancer--surprising reports.
    Speroff L
    Maturitas; 2005 Aug; 51(4):329-33. PubMed ID: 16039404
    [No Abstract]   [Full Text] [Related]  

  • 38. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
    Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
    J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
    Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone replacement therapy in women with past history of endometriosis.
    Soliman NF; Hillard TC
    Climacteric; 2006 Oct; 9(5):325-35. PubMed ID: 17000581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.